Patented pharma imports from India face 100% tariff by US
Our Bureau New Delhi US President Donald Trump's decision to impose a 100 per cent tariff on patented pharmaceutical imports--citing national security and supply chain risks following a Section 232 probe--is expected to have a mixed impact on India. Crucially...




















